Product Images Desvenlafaxine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Desvenlafaxine NDC 68151-5295 by Carilion Materials Management, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 2: Impact of Desvenlafaxine on Pharmacokinetics (PK) of Desipramine, Midazolam, Tamoxifen and Aripiprazole - image 01
This text contains information about Desvenlafaxine and its interaction with other drugs, such as Desipramine, Midazolam, Tamoxien, and Ariprazole. It also provides recommendations for dose adjustments based on fold change and relative to reference values. No dose adjustment is recommended for Desvenlafaxine ER 400 mg and Desveniafaxine ER 100 mg, while a reduction of up to one-half is recommended for Desvenlataxine ER 100 mg.*
Figure 3: Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) - image 02
This is a pharmacological document that provides information about the effect of renal and hepatic impairment on the recommended dosage of a drug. The text includes details about dosage adjustment for patients with different levels of renal and hepatic impairment, population description including gender and age, and fold change and 90% CI recommendations. However, the name of the drug is not available.*
Figure 1: Impact of Other Drugs on Desvenlafaxine Pharmacokinetics (PK) - image 03
Desvenlafaxine Structural Formula - image 04
Figure 4: Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5) - image 07
Figure 5: Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 6) - image 08
This appears to be a graph or chart that compares the estimated proportion of patients with relapse over time for two different treatments: Desvenlafaxine Extended-Release Tablets and a placebo. The x-axis displays time to relapse in days, while the y-axis represents the estimated proportion of patients with relapse, measured as a percentage. However, without a visual representation, it is difficult to interpret the results accurately.*
Label Image - lbl681515295
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.